Improving data sharing to increase the efficiency of antibiotic R&D

Greater investment is needed in antibiotic R&D, and more must be done to maximize the impact of such investments. More widespread data sharing, such as the recent joint data contribution from Merck and Kyorin to the Pew Charitable Trusts’ SPARK platform, has a key role.

The COVID-19 pandemic has provided a stark reminder not only of the need to be prepared before a public health crisis hits, but also of the essential role of antibiotics — in a pandemic and beyond. Unfortunately, when it comes to the growing dangers posed by antibiotic-resistant bacteria, the global level of preparedness does not match the magnitude of the threat. Indeed, recent declines in private investment in antibiotic R&D are staggering.